GlassScriptPhysician profile
Maaz A Abbasi
NPI 1679754725
$1,055.54
in general payments reported to CMS, 2019-2025
19 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $116 · 2021: $99.78 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $116.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $355.60 | 2019-2020 | |
| Vifor Pharma, INC. | $127.41 | 2019 | |
| Grt US Holding, INC. | $99.78 | 2021 | |
| Novo Nordisk INC | $63.89 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $61.38 | 2019 | |
| Amgen INC. | $59.14 | 2019-2025 | Krystexxa |
| Opko Pharmaceuticals, LLC | $32.70 | 2019 | |
| Medtronic, INC. | $30.94 | 2025 | Intellis Adaptivestim |
| Tandem Diabetes Care, INC. | $30.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.95 | 2025 | Ajovy |
| Genentech USA, INC. | $23.57 | 2019 | |
| Genzyme Corporation | $21.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.81 | 2019 | |
| Lilly USA, LLC | $20.18 | 2025 | Mounjaro, Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $18.51 | 2019 | |
| Strongbridge US INC. | $17.03 | 2019 | |
| Companion Medical, INC. | $13.86 | 2019 | |
| Shire North American Group INC | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maaz Abbasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.